Amgen Inc. (NASDAQ:AMGN) Holdings Lowered by Fulcrum Capital LLC

Fulcrum Capital LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,945 shares of the medical research company’s stock after selling 44 shares during the period. Fulcrum Capital LLC’s holdings in Amgen were worth $2,592,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Parallel Advisors LLC increased its holdings in Amgen by 0.8% in the 2nd quarter. Parallel Advisors LLC now owns 9,210 shares of the medical research company’s stock valued at $2,878,000 after buying an additional 70 shares during the period. Envestnet Asset Management Inc. boosted its stake in Amgen by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,408,785 shares of the medical research company’s stock worth $440,175,000 after acquiring an additional 107,134 shares during the last quarter. Seven Mile Advisory boosted its stake in Amgen by 15.3% during the 2nd quarter. Seven Mile Advisory now owns 852 shares of the medical research company’s stock worth $266,000 after acquiring an additional 113 shares during the last quarter. Hanson & Doremus Investment Management raised its holdings in Amgen by 3.6% during the 2nd quarter. Hanson & Doremus Investment Management now owns 1,592 shares of the medical research company’s stock worth $497,000 after buying an additional 55 shares during the period. Finally, Thompson Siegel & Walmsley LLC raised its holdings in Amgen by 49.4% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 38,677 shares of the medical research company’s stock worth $12,085,000 after buying an additional 12,784 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

NASDAQ AMGN traded up $7.08 during trading on Monday, hitting $269.31. 1,745,551 shares of the company’s stock were exchanged, compared to its average volume of 2,855,401. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market cap of $144.76 billion, a PE ratio of 34.48, a P/E/G ratio of 2.91 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The stock’s 50 day moving average price is $279.10 and its two-hundred day moving average price is $308.66.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.96 earnings per share. Research analysts expect that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.53%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 121.90%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AMGN shares. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Piper Sandler lowered their target price on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Wolfe Research started coverage on shares of Amgen in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Truist Financial reduced their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.